Next Article in Journal
Sex and SP-A2 Dependent NAD(H) Redox Alterations in Mouse Alveolar Macrophages in Response to Ozone Exposure: Potential Implications for COVID-19
Previous Article in Journal
Pharmacokinetics and Protective Effects of Tartary Buckwheat Flour Extracts against Ethanol-Induced Liver Injury in Rats
Review

Glutathione Supplementation as an Adjunctive Therapy in COVID-19

1
College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766-1854, USA
2
Department of Emergency Medicine, St Barnabas Hospital, Bronx, NY 10457, USA
3
Your Energy Systems, Palo Alto, CA 94301, USA
*
Author to whom correspondence should be addressed.
Antioxidants 2020, 9(10), 914; https://doi.org/10.3390/antiox9100914
Received: 4 August 2020 / Revised: 14 September 2020 / Accepted: 20 September 2020 / Published: 25 September 2020
Morbidity and mortality of coronavirus disease 2019 (COVID-19) are due in large part to severe cytokine storm and hypercoagulable state brought on by dysregulated host-inflammatory immune response, ultimately leading to multi-organ failure. Exacerbated oxidative stress caused by increased levels of interleukin (IL)-6 and tumor necrosis factor α (TNF-α) along with decreased levels of interferon α and interferon β (IFN-α, IFN-β) are mainly believed to drive the disease process. Based on the evidence attesting to the ability of glutathione (GSH) to inhibit viral replication and decrease levels of IL-6 in human immunodeficiency virus (HIV) and tuberculosis (TB) patients, as well as beneficial effects of GSH on other pulmonary diseases processes, we believe the use of liposomal GSH could be beneficial in COVID-19 patients. This review discusses the epidemiology, transmission, and clinical presentation of COVID-19 with a focus on its pathogenesis and the possible use of liposomal GSH as an adjunctive treatment to the current treatment modalities in COVID-19 patients. View Full-Text
Keywords: COVID-19; glutathione; cytokines; TNF-α; IL-6 COVID-19; glutathione; cytokines; TNF-α; IL-6
Show Figures

Figure 1

MDPI and ACS Style

Guloyan, V.; Oganesian, B.; Baghdasaryan, N.; Yeh, C.; Singh, M.; Guilford, F.; Ting, Y.-S.; Venketaraman, V. Glutathione Supplementation as an Adjunctive Therapy in COVID-19. Antioxidants 2020, 9, 914. https://doi.org/10.3390/antiox9100914

AMA Style

Guloyan V, Oganesian B, Baghdasaryan N, Yeh C, Singh M, Guilford F, Ting Y-S, Venketaraman V. Glutathione Supplementation as an Adjunctive Therapy in COVID-19. Antioxidants. 2020; 9(10):914. https://doi.org/10.3390/antiox9100914

Chicago/Turabian Style

Guloyan, Vika, Buzand Oganesian, Nicole Baghdasaryan, Christopher Yeh, Manpreet Singh, Frederick Guilford, Yu-Sam Ting, and Vishwanath Venketaraman. 2020. "Glutathione Supplementation as an Adjunctive Therapy in COVID-19" Antioxidants 9, no. 10: 914. https://doi.org/10.3390/antiox9100914

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop